Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
Abstract Aim Pemetrexed, a new generation antifolate drug, has been approved for the treatment of locally advanced or metastatic breast cancer. However, factors affecting its efficacy and resistance have not been fully elucidated yet. ATP-binding cassette (ABC) transporters are predictors of prognos...
Main Authors: | Jihui Chen, Zhipeng Wang, Shouhong Gao, Kejin Wu, Fang Bai, Qiqiang Zhang, Hongyu Wang, Qin Ye, Fengjing Xu, Hong Sun, Yunshu Lu, Yan Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-021-01842-x |
Similar Items
-
Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
by: Jihui Chen, et al.
Published: (2021-03-01) -
Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer
by: Bai F, et al.
Published: (2018-03-01) -
Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
by: Goyal Pankaj, et al.
Published: (2016-01-01) -
Pemetrexed induced pneumonitis
by: Binod Dhakal, et al.
Published: (2011-11-01) -
Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)